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The human 
 
 
 
-herpesviruses, EBV (or HHV-4) and Ka-
posi’s sarcoma-associated herpesvirus (KSHV or HHV-8)
are oncogenic viruses that induce a readily controlled lytic
infection followed by the establishment of life-long latency.
This quiescent state is maintained by the host immune sys-
tem. In most cases the persistent infection is asymptomatic
or accompanied by benign cellular proliferations. How-
ever, occasionally persistent 
 
 
 
-herpesvirus infection is asso-
ciated with the development of malignancies, including
Burkitt’s lymphoma, Hodgkin’s disease, nasopharyngeal
carcinoma, Kaposi’s sarcoma, and B cell lymphoprolifera-
tive syndromes. Most of these malignancies develop after
years of viral dormancy, and are associated with viral reacti-
vation. The important role for immune control in prevent-
ing the development of malignancies is illustrated by the
fact that immunosuppression, as a consequence of disease
(AIDS) or posttransplant immunosuppressive therapy, leads
to the development of EBV-associated lymphoproliferative
syndromes and lymphomas, and KSHV-associated Kaposi’s
sarcoma (1, 2). Because viral pathology is associated prima-
rily with reactivation of latent virus rather than with the
acute infection, it is essential to understand viral mecha-
nisms involved in reactivation from latency, and host
mechanisms of immune control.
For the human 
 
 
 
-herpesviruses, most of our knowledge
of latent infection has been derived from in vitro studies,
usually from cell lines. However, this approach does not
allow detection of host/virus interactions in the context of
a normal infection in vivo. Because the 
 
 
 
-herpesviruses
have coevolved with their host species, they are highly spe-
cies specific. Whereas some primate species can be infected
with EBV, these systems do not mimic natural infections,
and are of limited usefulness. SCID mice engrafted with
human lymphocytes have been used to study 
 
 
 
-herpesvi-
rus–associated malignancies, but these models have limited
utility as models of latent viral infection (3).
An experimental breakthrough came with the isolation
of a murine 
 
 
 
-herpesvirus, 
 
 
 
HV68 (4). Comparison of the
 
 
 
HV68 genome with other 
 
 
 
-herpesviruses has clearly es-
tablished 
 
 
 
HV68 as a 
 
 
 
-herpesvirus, more closely related to
the 
 
 
 
2-herpesviruses such as KSHV than the 
 
 
 
1-herpesvi-
ruses, such as EBV (5). Although all the 
 
 
 
-herpesviruses
share blocks of conserved genes, there is only limited ho-
mology between the genes controlling latency and trans-
formation among the viruses, because each of the viruses is
uniquely adapted to its host (5). Despite this, there are
striking biological similarities between 
 
 
 
HV68 and the hu-
man 
 
 
 
-herpesviruses in terms of the establishment and
immune control of the acute and latent stages of infection
(for reviews, see references 6–9), and 
 
 
 
HV68 latency genes
have been identified (10–13). 
 
 
 
HV68 thus provides a pow-
erful experimental system for studying fundamental aspects
of 
 
 
 
-herpesvirus virology, pathology, and immunity in an
easily manipulated small animal. Although 
 
 
 
HV68 is nei-
ther EBV nor KSHV, the information learned with this
murine system will undoubtedly be useful, and has already
led to a number of new insights into 
 
 
 
-herpesvirus biology
and pathogenesis. For example, a novel mechanism of
immune evasion, secretion of a broad-spectrum chemo-
kine-binding molecule, has been defined (14, 15). As this
protein also binds human CC and CXC chemokines, it
may have therapeutic potential (6). In addition, the mouse
model has been used to implicate 
 
 
 
-herpesviruses in vascu-
lar disease (16–18) and has been used as an experimental
model for vaccine development (for a review, see reference
19). Finally, analysis of infection with mutant viruses that
lack specific gene function provides a powerful in vivo ex-
perimental approach for studying host/virus interactions.
In this issue, Gangappa et al., have taken advantage of
the 
 
 
 
HV68 model to analyze the in vivo role of two viral
gene homologues for cellular genes involved in regulating
apoptosis and cell cycle progression (20). Bcl-2 is an anti-
apoptotic member of the bcl-2 family and D-cyclin func-
tions in cell cycle progression from G1 to S phase. Due to
the lack of appropriate animal models, it had not been
possible to determine the function of the v-bcl-2 and v-cyclin
genes encoded by the human 
 
 
 
-herpesviruses in vivo. For
example, efforts to determine the role of the EBV bcl-2
homologue, BHRF1, in EBV infection by comparing the
ability of EBV wild-type and BHRF1-deficient viruses to
infect and transform primary lymphocytes, showed no differ-
ences (21). Despite this negative result, the finding that
BHRF1 was universally present in the EBV genome
suggested an essential role. 
 
 
 
HV68 was mutated by ho-
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mologous recombination to be deficient in either v-bcl-2
(20) or v-cyclin (22, 23). Analysis of mice infected with the
mutant viruses showed that neither v-cyclin nor v-bcl-2
were required for viral replication in vitro or during acute
infection in vivo, although the v-cyclin–deficient virus was
shown to have a replicative disadvantage following coin-
fection with wild-type virus (23). Pathological effects of the
acute infection, assessed in terms of lethality in immunode-
ficient mice and lethal meningitis after intracerebral admin-
istration to weanling mice, showed no differences between
the wild type and mutant viruses (20, 22). In contrast to the
lack of an effect in the acute stages of infection, mutation of
either v-bcl-2 or v-cyclin prevented reactivation from la-
tency, assessed by ex vivo reactivation assays (20, 22, 23).
Viral reactivation is measured by the ability of latently in-
fected cells to spontaneously reactivate and cause cell lysis
when plated in vitro on a susceptible cell monolayer. Al-
though it hasn’t been directly demonstrated, the assump-
tion is that ex vivo reactivation accurately reflects in vivo
viral reactivation. Gangappa et al. took full advantage of the
 
 
 
HV68 mouse model by examining the consequences of
chronic infection in immunocompromised mice, so that
the pathological effects of viral reactivation in the absence
of immune control could be assessed in terms of the devel-
opment of chronic virus-associated pathology. A major
consequence of chronic 
 
 
 
-herpesvirus infection in man is
the development of malignancies. Although 
 
 
 
HV68 is also
associated with increased frequencies of malignancies in
mice (24), this isn’t an ideal experimental end point, as on-
cogenesis is an incompletely understood, slowly develop-
ing, multi-step process, of which viral infection is only one
component. However, persistent 
 
 
 
HV68 replication in im-
munocompromised mice deficient for the IFN-
 
 
 
 receptor
(IFN
 
 
 
R-deficient mice) has been shown to result in the
development of large vessel arteritis (16, 17). Not only did
this and other (18) studies support an etiological role of
 
 
 
-herpesviruses in the development of human vascular dis-
ease, the rapid onset of arteritis provided a predictable and
quantitative read-out of chronic 
 
 
 
HV68 infection in the
mouse. Analysis of immunocompromised mice infected
with the v-bcl-2- and v-cyclin–deficient viruses showed
markedly reduced pathological consequences of chronic vi-
ral replication, assessed by decreased lethality and reduced
incidence of arteritic lesions. Infection of immunocompro-
mised IFN
 
 
 
R-deficient mice allowed the consequences of
viral reactivation, in this case persistent replication, to be
readily observed. In addition, the finding that v-bcl-2 and
v-cyclin are not essential for acute viral replication, but are
required for reactivation from latency, persistent viral repli-
cation, and disease during chronic infection, allowed the
authors to conclude that persistent viral replication was a
consequence of reactivation from latency, rather than cel-
lular transmission of lytic virus, and that different viral
genes are required for acute and persistent replication.
 
 
 
HV68, EBV, and KSHV all coopt the function of cel-
lular bcl-2 and D-cyclin, but each virus has adapted the cel-
lular function uniquely. Members of the bcl-2 family con-
tain up to four bcl-2 homology domains, which are
required for heterodimer formation and interaction with
other cellular proteins to generate pro- and antiapoptotic
molecules. 
 
 
 
-herpesvirus bcl-2 homologues mimic the an-
tiapoptotic functions, but not the pro-apoptotic functions
of the cellular bcl-2 family by conserving only the BH1 and
BH2 domains (EBV and KSHV) or just the BH1 domain
(
 
 
 
HV68) (25, 26). There are also important differences
among the 
 
 
 
-herpesviruses regarding the mechanisms by
which they coopt the function of the mammalian D-type
cyclins (D1, D2, and D3). EBV does not encode a cyclin
homologue. Rather, EBV infection, through expression of
LMP-1 up-regulates expression of the host cyclin D2.
KSHV and 
 
 
 
HV68 both contain open reading frames pre-
dicted to encode proteins homologous to the mammalian
D-type cyclins. The highest level of sequence conservation
is within the cyclin box, a domain essential for cyclin-depen-
Figure 1. MHV-68 reactiva-
tion from latency is dependent
upon both v-cyclin and v-bcl-2.
A likely scenario is that v-cyclin
allows cell cycle progression that
is essential for the initiation of
viral replication, and that v-bcl-2
prevents the subsequent apopto-
sis of the cycling cell. In an immu-
nocompetent mouse, viral recru-
descence and spread is controlled
by the host immune system.
However, in the absence of effec-
tive immune control, persistent
replication leads to pathology.
Important targets for immuno-
therapy include the viral bcl-2
and cyclin homologues and anti-
viral immune function. 
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dent kinase binding. The viral proteins do not, however,
exactly mimic the function of their host counterparts. For
example, the specificity of binding of v-cyclin to cyclin-
dependent kinases is relaxed, and normal regulation is dis-
rupted, perhaps due to structural differences between the
viral and cellular cyclins.
The similar phenotype of the 
 
 
 
HV68 mutant viruses de-
ficient in v-bcl-2 and v-cyclin suggests that regulation of
apoptosis and cell cycle are both important for reactivation
from latency. Latently infected cells appear to be arrested at
a specific point in their cell cycle. Therefore, the require-
ment for v-cyclin for reactivation from latency is consistent
with the need for cell cycle progression to allow efficient
DNA replication during virus reactivation. However, viral
reactivation and/or cell cycle progression trigger viral or
host apoptotic pathways, so there is an additional require-
ment for antiapoptotic mechanisms, provided by v-bcl-2.
A delicate balance between cell cycle progression and pre-
vention of apoptosis must be maintained, and disruption of
this balance may contribute to the development of malig-
nancies. Virus reactivation is presumably controlled by the
host immune system in immunocompetent individuals.
Immune control of the acute lytic infection has been well
characterized (6, 7), but less is known about immune con-
trol of reactivation from latency. Control of virus reactiva-
tion is likely to be mediated by distinct mechanisms, in-
cluding not only CD8
 
 
 
 T cells, but also IFN-
 
 
 
 (27) and
antibody (28).
The link between v-cyclin and v-bcl-2 expression and
viral reactivation from latency and pathology established by
Gangappa et al., suggest that the 
 
 
 
-herpesvirus–encoded
v-cyclin and v-bcl-2 are important targets for therapeutic
intervention (Fig. 1). One straightforward approach might
be antisense therapy. In this regard, antisense therapy in
oncology is undergoing a renaissance, and encouraging re-
sults are being obtained with “second-generation” anti-
sense oligonucleotides, including bcl-2, in conjunction
with chemotherapy in control of a variety of malignancies
(29). Feasibility is further established by the observation
that antisense oligonucleotides specific for v-bcl-2 encoded
by EBV (BHRF1) effectively inhibit antiapoptotic function
(30). Targeting the viral genes would allow early interven-
tion, to prevent viral reactivation and the onset of malig-
nancies in immunosuppressed patients. Preventative in-
tervention is particularly indicated for controlling the
development of malignancies in high risk scenarios specifi-
cally associated with viral reactivation, such as AIDS pa-
tients or after immunosuppressive transplant therapy. In ad-
dition, if the association between viral reactivation and
vasculitis and atherosclerosis in the mouse is borne out in
the human, ultimately such approaches might be useful in
the prevention and/or control of human vascular disease.
However, it is clear that usurping cellular control of apop-
tosis by the 
 
 
 
-herpesviruses is more complex than the ex-
pression of v-bcl-2. In addition to encoding a v-bcl-2,
EBV proteins EBNA-4 and LMP-1 up-regulate transcrip-
tion of cellular bcl-2 and family members (31–33), LMP-1
interacts with TRAFs and TRADD (34), and E1B19K in-
teracts with the proapoptotic protein, Bax (35). Recently,
expression of an EBV-bcl-2 antagonist, BALF1, has been
reported (36). Likewise, KSHV encodes other inhibitors of
apoptosis, including v-FLIP, which is an inhibitor of Flice
(37). Thus, therapeutic targeting of v-bcl-2 might be only
partially effective, or may require combination treatment
with several oligonucleotides.
A second target for therapeutic intervention is enhance-
ment of immune function. The effectiveness of this strategy
is illustrated by the success with adoptive transfer of EBV-
specific cytolytic T cells as therapy for EBV-associated lym-
phoproliferative disorders, which are complications of bone
marrow transplantation (38). In addition, we have recently
demonstrated an important role for humoral immunity in
control of 
 
 
 
-herpesvirus latency (28), supporting the ratio-
nale for therapeutic passive transfer of immune serum,
which is being addressed systematically in clinical trials (39,
40). Additional therapeutic targets might include enhance-
ment of the antiviral IFN-
 
 
 
 response (20).
In summary, although there are important differences in
the murine and human 
 
 
 
-herpesviruses, the availability of
the 
 
 
 
HV68 mouse model is a major break-through in the
field, and it’s clear that much can be learned from appropri-
ate interpretation of in vivo studies with this model. The
current studies make important progress in understanding
mechanisms involved in reactivation from latency, a key
step in chronic viral pathogenesis. In addition, 
 
 
 
HV68 in-
fection of immunodeficient mice provides an important ex-
perimental system for testing new therapeutic approaches for
controlling persistent viral replication and pathology (Fig. 1).
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